Go Pro
NASDAQ:AFIB

Acutus Medical (AFIB) Stock Price, News & Analysis

Acutus Medical logo

About Acutus Medical Stock (NASDAQ:AFIB)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
6,201 shs
Market Capitalization
$3 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acutus Medical is a commercial-stage medical technology company specializing in the development and commercialization of advanced cardiac mapping systems designed to improve the diagnosis and treatment of complex cardiac arrhythmias. The company’s flagship product, AcQMap, integrates high-resolution ultrasound imaging with electrical mapping to deliver comprehensive three-dimensional visualizations of arrhythmic sources, aiding electrophysiologists in the targeted management of conditions such as atrial fibrillation.

The AcQMap system employs a noncontact, high-density mapping catheter alongside ultrasound-based anatomical reconstruction to enable rapid, global mapping of cardiac chambers. By capturing electrical and anatomical data concurrently, the technology can reduce procedural times and enhance ablation precision compared with traditional point-by-point mapping approaches. Acutus Medical also provides clinical training, technical support and service programs to help health-care institutions incorporate its mapping solutions into routine electrophysiology workflows.

Founded in 2011 and headquartered in Carlsbad, California, Acutus Medical has secured regulatory clearances including FDA approval in the United States and CE marking in Europe. The company maintains a growing commercial presence across North America and key European markets, serving leading cardiac centers that manage complex arrhythmias. This global footprint reflects Acutus’s focus on expanding access to high-resolution diagnostic tools for atrial and ventricular mapping.

Under the leadership of President and Chief Executive Officer Robert E. White, Acutus Medical has transitioned from a development-stage enterprise to a public company with an emphasis on innovation. The firm continues to invest in research and development initiatives aimed at refining its mapping algorithms and broadening its electrophysiology portfolio, seeking to address a wider range of arrhythmic conditions and enhance overall patient outcomes.

AI Generated. May Contain Errors.

Receive AFIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acutus Medical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AFIB Stock News Headlines

AFIB Acutus Medical, Inc. - Seeking Alpha
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance estimates it could unlock $400 trillion - but analyst Jeff Brown, who was consulted by Congressional offices on the legislation, believes the real figure could reach $2.6 quadrillion. Brown says this shift will pour onto a new type of investment exchange - and he's showing investors how to position themselves starting with just $100.tc pixel
Acutus Medical Reports Full Year 2024 Financial Results
Acutus Medical Announces Operational Downsizing
Acutus Medical Reports Q3 2024 Financial Results
See More Headlines

AFIB Stock Analysis - Frequently Asked Questions

Acutus Medical, Inc. (NASDAQ:AFIB) released its quarterly earnings data on Thursday, November, 11th. The company reported ($0.94) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by $0.02. The business earned $4.60 million during the quarter, compared to analyst estimates of $6.02 million. Acutus Medical had a negative net margin of 272.74% and a negative trailing twelve-month return on equity of 311.64%.

The following companies are subsidiaries of Acutus Medical: Acutus Medical N.V..

Acutus Medical (AFIB) raised $126 million in an initial public offering on Thursday, August 6th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, BofA Securities and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Shares of AFIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acutus Medical investors own include Enterprise Products Partners (EPD), NVIDIA (NVDA), Arista Networks (ANET), Meta Platforms (META), PayPal (PYPL) and Rio Tinto (RIO).

Company Calendar

Last Earnings
11/11/2021
Today
8/04/2026
Next Earnings (Estimated)
8/07/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:AFIB
CIK
1522860
Employees
340
Year Founded
2011

Profitability

EPS (Trailing Twelve Months)
($0.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$81.66 million
Net Margins
-272.74%
Pretax Margin
-30.32%
Return on Equity
-311.64%
Return on Assets
-11.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.85
Quick Ratio
1.57

Sales & Book Value

Annual Sales
$7.16 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.03) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
29,912,000
Free Float
28,228,000
Market Cap
$3 thousand
Optionable
No Data
Beta
5.67

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:AFIB) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners